Dalpiciclib and hormone therapy for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman 18 years or older, with known menopausal status (postmenopausal, premenopausal, or perimenopausal).
- You have a type of breast cancer called hormone receptor positive (HR+) and HER2-negative, confirmed by biopsy.
- Your cancer is early stage (IIA to IIIC) and has not spread to other parts of the body (stage IV or inflammatory breast cancer is excluded).
- You had surgery to remove the cancer, and it has been less than 12 months since that surgery.
- You are in generally good health, with an ECOG status of 0 or 1 (able to carry on normal activities or do light work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called Dalpiciclib given after surgery to help prevent early-stage breast cancer from coming back. It is for women with hormone receptor-positive (HR+) and HER2-negative breast cancer that has not spread to other parts of the body.
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
This Phase 2 trial tests dalpiciclib (a cancer medicine) added to standard hormone therapy for women with advanced, hormone-receptor–positive and HER2-negative breast cancer that has serious “visceral crisis” symptoms (like fluid buildup, liver issues, or other urgent organ involvement). It aims to see whether this combination can shrink cancer and improve safety compared with hormone therapy alone.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.